Related Experiment Video

Updated: Feb 8, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.1K

Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer

Xinwei Huang1,2, Hong Zhang3, Xiaoran Guo2

  • 1Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming City, 650504, Yunnan Province, China.

Journal of Hematology & Oncology
|June 30, 2018
PubMed

Insights

Insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1) has dual roles in cancer, acting as both an oncogene and tumor suppressor. Understanding its regulation by non-coding RNAs is key for cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Developmental Biology

Background:

  • Insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1) is crucial in development and cancer.
  • IGF2BP1 regulates mRNA targets, impacting tumor proliferation, invasion, and chemo-resistance.
  • IGF2BP1 is linked to poor survival and metastasis, traditionally viewed as an oncogene.

Purpose of the Study:

  • To elucidate the contradictory functions of IGF2BP1 in development and cancer.
  • To explore the regulatory roles of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) on IGF2BP1.
  • To understand the intricate interplay between IGF2BP1, mRNAs, and non-coding RNAs (ncRNAs) in tumorigenesis.

Main Methods:

  • Review of existing literature on IGF2BP1.
  • Analysis of IGF2BP1's tissue distribution and expression patterns.
  • Focus on the modulation of interconnectivity between IGF2BP1 and its targets.

Main Results:

  • IGF2BP1 exhibits both oncogenic and tumor-suppressive functions, with details remaining unclear.
  • miRNAs and lncRNAs are identified as direct regulators of IGF2BP1.
  • IGF2BP1's role in controlling gene expression impacts tissue development and cancer progression.

Conclusions:

  • Further elucidation of IGF2BP1-mediated post-transcriptional gene regulation is necessary.
  • Understanding the IGF2BP1 network with ncRNAs is vital for comprehending development and tumorigenesis.
  • Inhibitors targeting IGF2BP1 and its pathways show potential for cancer therapy.
Keywords:
CRD-BPCancerIGF2 mRNA-binding proteinIGF2BPIMPVICKZ

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.2K
2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes08:23

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

Published on: August 6, 2018

11.9K

Related Concept Videos

Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
575
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
488
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
332
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
611
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
11.9K
Predicting Products: SN1 vs. SN202:27

Predicting Products: SN1 vs. SN2

Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
17.4K